Goal
Prevent and treat SARS, COVID-19 and related coronavirus infections using traditional Chinese herbal medicines.
Problem
Lack of specific, effective antiviral drugs for SARS-like viruses and the need for low-cost, readily available therapeutic options.
Concept Summary
A series of Chinese-medicine compositions-oral liquids, injections, granules, decoctions and suspensions-prepared from multiple medicinal herbs (e.g., Herba Solidaginis, Scutellaria baicalensis, honeysuckle, Echinacea, etc.) that are claimed to possess antiviral, anti-inflammatory and immune-modulating activities against SARS-CoV, MERS-CoV, influenza and other respiratory viruses.
Detailed Description
The article compiles abstracts of ten patents describing various herbal formulations. The inventions detail raw-herb selection, extraction (water, ethanol, 70 % alcohol), concentration, and final dosage forms (oral liquid, spray, injection, granule, decoction). Claims include high recovery rates in canine coronavirus (>=95 %), inhibition of SARS virus replication in VeroE6 cells at 100 ug ml^-^1, and broad-spectrum activity against multiple respiratory viruses. Preparation methods involve crushing herbs, boiling, vacuum concentration, mixing with excipients (sugar, starch, sodium sulfate) and drying. The formulations are marketed as safe, low-cost, and effective for preventing or treating viral pneumonia, SARS, influenza, and related illnesses.
Principles
- Traditional Chinese Medicine (TCM) theory of heat-clearing and toxin removal
- Phytochemical antiviral activity (flavonoids, alkaloids, polysaccharides)
- Synergistic multi-herb combination
- Extraction and concentration of active constituents
Scientific Domains
Materials
- Herba Solidaginis (goldenrod)
- Scutellaria baicalensis
- Lonicera japonica (honeysuckle)
- Echinacea purpurea
- Peganum harmala (Syrian rue)
- Tilia cordata (tillet)
- Glycyrrhiza glabra (licorice)
- Fructus evodiae
- Codonopsis pilosula
- Fresh ginger
- Chinese yam
- Longan aril
- Brucea javanica
- Pulsatilla
- Lygodium japonicum
- Griffith streptocaulon
- Orange peel
- Herba menthae spicatae
- Delavay gerbera root
- Radix angelicae
- Hemp-leaved vitex root
- Ordos wormwood
- Anisopappus chinensis
- Moldavian dragon's head
- Semen armeniacae amarae
- Bulbus fritillaria thunbergii
- Pericarpium citri reticulatae viride
- Succus bambusae
- Chinese ephedra
- Canton hedyotis herb
- Ligusticum wallichii
- Smoked plum
Mechanisms of Action
- Direct viral replication inhibition
- Immune system modulation
- Anti-inflammatory effects
- Reduction of oxidative stress
Applications
- Treatment and prevention of SARS, COVID-19, MERS and other respiratory viral infections
- Veterinary antiviral therapy for dogs and calves
- Low-cost community health remedies
Claimed Performance
Recovery rates up to >=95 % in canine coronavirus; complete inhibition of SARS virus in cell culture at 100 ug ml^-^1; broad-spectrum efficacy against influenza, rhinovirus, RSV, adenovirus, etc.; rapid clinical improvement reported in patents.
Experimental Evidence
One patent reports a canine coronavirus recovery rate >=95 %; another cites VeroE6 cell assay showing complete SARS inhibition at 100 ug ml^-^1; other abstracts claim clinical effectiveness without quantitative data.
Replication Status
No explicit independent replication or peer-reviewed studies are mentioned in the abstracts.
Limitations
- Lack of randomized clinical trials in humans
- Variability of herb quality and composition
- No standard dosing guidelines
- Potential herb-drug interactions
Red Flags
- Claims of high cure rates without peer-reviewed data
- Absence of disclosed clinical trial methodology
- Potential for unverified health claims
